Tirzepatide-ECHEMI
2078 Inquiries
2023788-19-2
Pharmaceutical Grade
Any China Port
100 G/ BAG
2024-12-06
API,Intermediate
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.
Basic Info-
Product Name:
Tirzepatide
Other Name:LY3298176;
CAS No.:2023788-19-2
Molecular Formula:C225H348N48O68
Molecular Weight:4813
EC Number:200-001-8
Categories:
Characteristics-
Appearance:
White to off-white
Research-
Class:
Dual agonist — GIPR, GLP-1R
Status:FDA-approved (Mounjaro / Zepbound)
Mechanism:Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.
EC50 (Human GLP1R):0.934 nM
EC50 (Human GIPR):0.0224 nM
Source:Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI
Clinical Development:NCT03954834; NCT03987919; NCT03882970; NCT03730662; NCT04039503
FDA:Mounjaro, Zepbound (approved 2022-05-13)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Distributor
-
Main Products:
API,Intermediate
-
Payment Terms:
TT against copy of documents,L/C
-
Average lead Time:
30
-
Total Annual Revenue:
Above $100 million
-
Total Employees:
201-300
About Echemi Pharmaceutical
Echemi’s philosophy is to seek for higher quality, to explore frontier area. The progress of human society, the extension of life expectancy, and the conquest of disease are all derived from the numerous businesses and individuals who have quietly dedicated themselves in the pharmaceutical industry. It’s the controlling of supply chain quality that ensures the efficacy. It’s the continuous exploration that promotes the development of the pharmaceutical industry and benefits more future generations. The pursuit of high quality requires all partners of Echemi Pharmaceutical to be screened, whether its certificate, qualification or scale. In the field of renewal, we will embrace all new changes and make more contributions to the development of pharmaceutical industry.
Advantage for Pharmaceutical
• Having been working in pharmaceutical field for more then 15 years, we have experienced regulatory team, quality control team, sourcing team, technical support team, and logistics team. And we are familiar with the regulatory requirements from different areas, can offer tailored service for our customers.
• We have hundreds of strategic partners for APIs, intermediates, and custom synthesis. All of our partners are ready to support our customers with documents, and be audited.
• We can offer custom synthesis for some new chemical structures and some materials which there are no reliable suppliers.
Product Category
We care for human and animal health and we are committed to creating a better social environment.
• Human API
• Intermediate
• Veterinary API
• Agrochemical
• Fine Chemical
• Custom Synthesis
-
-
Inquiry History2078 Inquiries
Country Product Purchase Quantity Date Posted 
United States
2023788-19-2 in unlabeled vials 10, 15 and 30 mg
10 Feb 14, 2024
United States
Peptide drug GLP-1 Agonists Tirzepatide CAS 2023788-19-2 Weight loss 399 Inquiries
10 MG Apr 3, 2024
United States
Tirzepatide Raw Powder Weight Loss Peptides CAS No 2023788-19-2 Tirzepatide Injection Peptides
2 MT Dec 13, 2025 
Hongkong, China
2023788-19-2
1 KG Aug 13, 2026 
Germany
2023788-19-2
1 MG Jun 18, 2026
United States
Tirzepatide 2023788-19-2
2 Feb 19, 2024
United States
Tirzepatide 2023788-19-2
10 G Oct 31, 2023
United States
2023788-19-2 Retatrutide
1 G Sep 22, 2023
United States
2023788-19-2 Trizepatide
10 MT Oct 29, 2023
United States
Trizepatide 2023788-19-2 Raw Material LY3298176 Tirzepatide powder
1 Dec 2, 2025
United States
Peptide drug GLP-1 Agonists Tirzepatide CAS 2023788-19-2 Weight loss
2 KG Oct 20, 2023
United States
Fat Burning Peptides Tirzepatide 10mg/Vial 15mg/Vial Tirzepatide CAS: 2023788-19-2
1 MT Jan 25, 2024
United States
Pharmacy Grade CAS 2023788-19-2 Tirzepatide 99% White powder Tirzepatide
1 MT Oct 20, 2023
United States
supply Tirzepatide Safe Material Shipping Trizepatide 2023788-19-2 Raw Tirzepatide powder
10 MG Apr 4, 2024
United States
COA Offer Top quality Weight Loss Peptides Tirzepatide 10mg/vial GLP-1 2023788-19-2
1 MT Sep 10, 2023 
Kenya
Janoshik Test Tirzepatide 99% White powder High Quality Tirzepatide Weight loss CAS 2023788-19-2
30 MG Dec 26, 2025
United States
Ex-factory price tirzepatide T30 10vials 30mg kit cas 2023788-19-2 for weight loss peptide
10 Dec 30, 2024 
United Kingdom
Manufacturer supply high quality hot sale lowest price Tirzepatide CAS NO,2023788-19-2 99% powder 2023788-19-2 Claire
100 G Nov 4, 2023 
Canada
99.9% Purity GLP-1 Injection Weight Loss Peptides Liraglutide Retatrutide Tirzepatide Semaglutide 5mg 10mg CAS 2023788-19-2
2 MT Oct 22, 2023 
Poland
TIRZEPATIDE
10 MG Feb 18, 2026 Post an enquiry for this product